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prices for medicines awarded an ASMR (additional medical benefit) rating of I to 
III, and those with an ASMR IV in relation to medicines recently rated at ASMR 
levels I to III, will not be lower than the lowest price in the 4 main reference EU 
markets, for 5 years. Our aim is to assess whether this price guarantee has been 
respected for price cuts published in the Official Journal between January 2013 and 
July 2015. Methods: Based on MAPI® database collecting price cuts and ASMR 
ratings, we screened medicines granted relevant ASMRs, and identify those affected 
by at least one price cut within the 5-years period following their admission to 
reimbursement. Results: As of June 11, 2015, amongst medicines with price cuts 
despite an ASMR I to III or IV granted in less than 5 years, 12 had been admitted to 
reimbursement for more than 5 years, recent ASMR being granted to extended indi-
cations. Within the 5 years following their reimbursement, price cuts were observed 
for only 4 medicines granted an ASMR III (abiraterone, boceprevir, telaprevir and 
vemurafenib) and 4 granted an ASMR IV (apixaban, denosumab, solifenacin and 
ulipristal acetate). ConClusions: Overall, the 5-years price stability for innova-
tive medicines fulfilling the criteria set by the agreement is verified, price cuts 
concerning mainly mature products. Price cuts for qualified medicines within the 
first 5 years may be due to changes in prices in reference countries, budget impact 
concerns or other reasons kept confidential.
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objeCtives: Since October 2013, companies are requested to submit a cost-effec-
tiveness analysis when applying to reimbursement for pharmaceuticals or medical 
devices and claiming from a major to a moderate additional medical benefit versus 
comparators (ASMR/ASA/ASR I-III). Efficiency appraisals are published after comple-
tion of the procedure and prices made public. They include critics of the methodol-
ogy classified as minor, important and/or major limitations. Our aim is to present an 
analysis of these appraisals. Methods: Results of appraisals in terms of ICERs and 
limitations will be presented along with the medical assessment (target population, 
therapeutic area, SMR/ASMR) and the annual treatment price. Limitations will also 
be detailed. Results: As May 2015, a cost/effectiveness analysis was required for 
28 pharmaceuticals and 1 medical device. Five (alemtuzumab, dolutegravir, rioc-
iguat, sofosbuvir, trastuzumab emtasine) have been published. They concern dif-
ferent therapeutic areas (pneumology, infectiology, oncology, neurology) and target 
populations (from 1,000 patients in CTEPH to 130,000 in hepatitis C). ASMR granted 
vary from IV to II, with one medicine granted a negative SMR. Efficiency has been 
assessed either for the full indication of the market authorization or only a restricted 
one. The ICERs varied from less than € 20,000 to almost € 200,000/QALY at companies 
requested prices, with treatment cost varying from € 6,000 to € 60,000. In case of 
major limitations, efficiency is not assessed, with negative impact on the following 
price negotiations. In case of important limitations, results have to be cautiously 
interpreted. ConClusions: These 5 published assessments provide key learnings 
about the French HTA body’s expectations. More evidence impact on the price nego-
tiation is expected with upcoming assessments to be published and through ICERs 
calculation with published prices.
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objeCtives: To asses and obtain data on the proper use of drugs and present irra-
tional drug use pattern by medical practitioners that weather the patients receive 
the medicines, weather these are appropriate for their clinical needs, in proper doses, 
for appropriate periods of time, weather cost effective and were dispensed prop-
erly. Methods: This study was designed to asses’ irrational drug use pattern which 
is a great concern of the entire world and WHO in general and in our country in 
particular. For this study we used the WHO indicators utilizing the services of trainee 
Pharmacists in two major city Hospitals. This study was conducted from April, 15th 
2014 to May, 14th 2014. Data was collected using patient’s prescriptions and direct 
patient communication using a structured check list for the prescribing indicators 
including number of drugs per prescription, number of antibiotics, number of injec-
tions, number of steroids and number of food supplements. The patient care data 
was directly interpreted and analyzed over the dispensing counters. Results: The 
results showed that in both hospitals (860 prescriptions), the average number of drugs 
per prescription were 5, the patients were prescribed antibiotics at least two antibiot-
ics per prescription (40%), (The antibiotics were mainly Amoxicillin, Co-amoxiclav, 
Ciprofloxacin, Norfloxacin and Flouroquinolones. It was also observed that in some 
cases the antibiotics of choice were not recommended). The percentage of injec-
tions, steroids and food supplements were 20% each. The percentage of proper doses, 
proper timing, cost effectiveness and proper dispensing was 70%, 60%, 20% and 20% 
respectively. This irrational prescribing pattern/habit of the medical practitioners was 
observed in both the hospitals. ConClusions: This study indicates that this type of 
irrational practice is the reflection of state and regulatory affairs in the country which 
need strict regulations and strategies for drug prescriptions and dispensing including 
the utilization of services of more Pharmacists.
PHP303
lAW ProjEct 7169/2014 And HEAltH Policy in BrAziliAn suPPlEmEtAry 
sEctor
Silva FH, Fonseca LM
ANS, Rio de Janeiro, Brazil
objeCtives: To discuss about the LP 7169/2014, the new Law Project that wants to 
regulate the conflicts’ mediation in Brazil, and to describe the successful experi-
ence of the conflicts’ mediation between health plans and consumers promoted 
guidance on how clinicians should approach a conversation with patients about 
economic value. ConClusions: Our review demonstrates that efforts to incor-
porate economic data to support clinical decision-making are still in its early 
stages. A number of societies consider basic cost or burden elements as part of 
topic selection or recommendation formulation. None of the reviewed societies 
have systemically incorporated economic assessment in a manner that would 
enable the physician and the patient to jointly make an informed decision based 
on value. Researchers have a clear role to play in helping guideline developers 
incorporate the patient perspective in discussions of cost/cost-effectiveness, and 
helping physicians develop tools to communicate value.
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objeCtives: Health information technologies represent a valuable tool to pro-
mote a better use of medicines and optimize health expenditure. The purpose of 
this study is to assess advantages provided by the use of technological supports 
to detect medication errors (MEs) in a community setting. Methods: In 2011, 
the Local Health Unit (LHU) Caserta established an innovative web platform, the 
Saniarp PHT. This platform allows tracking of drug prescriptions included in the 
Hospital-Territory Formulary (PHT), and puts in network medical specialists working 
in Prescribing Centers of regional relevance, community pharmacies and General 
Practioners (GPs). Through this platform, LHU can perform real time checks on 
prescription, distribution and inventory of PHT drugs. A multidisciplinary team 
checks each prescription that LHU received and confirm or not the distribution. A 
retrospective cross-sectional analysis was performed (Sept 2013-Sept 2014) to evalu-
ate frequencies and types of ME occurred during the observation period. MEs were 
then classified according to MedDRA Preferred Term Groups on the basis of Draft 
World Health Organization (WHO) ME Classification. Results: During the observa-
tion period, 1233 MEs were detected. The most frequent MEs were “Circumstance 
or information capable of leading to medication error” (n= 761, 61,7%), followed by 
“Intercepted drug prescribing error” (n= 194, 15,7%). The main anatomical groups 
most frequently associated with MEs were nervous system agents (48%), antineo-
plastic and immunomodulating agents (16%) and systemic anti-infectives agents 
(11,5%). ConClusions: Preventing MEs is important not only for patients’ safety, 
but also to optimize financial resources. Our data show that technological sup-
ports give consistent advantages in the MEs’ detection. Moreover, these tools are 
useless if not associated with a professional figure like pharmacist, or, even better, 
a multidisciplinary team.
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objeCtives: Japan Council for Quality Health Care (JCQHC) is the only organiza-
tion to accredit hospitals according to its evaluation standard in Japan. This study 
aims to explore the association between accreditation scores on health care quality, 
patient safety and medical ethics, and the hospital characteristics. Methods: As of 
March 2nd, 2012, 2,437 hospitals were accredited by JCQHC. In those hospitals, 848 
hospitals have been participating in the public disclosure. Out of 848, we extracted 
454 hospitals accredited according to version 5.0 JCQHC evaluation standards from 
the JCQHC database and we evaluated their scoring about 2nd area of “patients’ 
rights and systems for securing patient safety”. The accreditation surveyors rated 
each item from 1 (poor) to 5 (excellent). Results: The 454 hospitals included 41 
university hospitals (UHs) and 411 general hospitals (GHs). The mean scores for 
411 GHs and 41 UHs of 2.1.2 “Policy on professional ethics is clearly indicated” 
were 3.46±0.518 and 3.41±0.499 (p= 0.593). And those of 2.1.3 “Policy on clinical eth-
ics is clearly indicated” were also 3.22±0.478 and 3.37±0.488 (p= 0.070). There were 
statistically no significance between GHs and UHs. Similarly, the mean scores for 
411 GHs and 41 UHs of 2.1.4 “Policy on clinical trial studies is clearly indicated” 
were 3.87±0.368 and 4.00±0.224 (p= 0.027). And, those of 2.1.5 “Policy on clinical 
researches is clearly indicated” were 3.75±0.473 and 3.93±0.264 (p= 0.018). There were 
statistically significances between two hospital groups. Furthermore, there were 
statistically significances between the items of ethics and research respectively 
(p< 0.001). Hence, the scores of items of clinical ethics have to be patient-centered 
were lower, but those of items regarding researches and trials. ConClusions: 
These findings led to the conclusion that health care professional at university 
hospitals might lack a sense of ethics and be more interested in clinical researches 
than general hospitals.
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objeCtives: Admission to reimbursement in France for drugs is implemented 
conventionally through framework agreements between the industrial association 
(LEEM) and the Economic Committee (CEPS) encompassing price setting, expendi-
ture regulation and industrial policy. According to the agreement currently enforced, 
